Oncology

AstraZeneca has been developing cancer medicines for more than 40 years. Many of these have increased survival rates for patients in the UK and around the world. Even as R&D continues to push boundaries in how we understand and fight cancer, there is still more to do. 

We are at the heart of oncology R&D in the UK and are committed to advancing the science of oncology to deliver life-changing medicines. Our ambition is to eliminate cancer as a cause of death through scientific discovery and collaborations and ensure that these reach people in most need.

  • Faslodex (fulvestrant) is indicated: 

    • as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: 

    - not previously treated with endocrine therapy, or

    - with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy.

    • in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy (see section 5.1).

    In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone (LHRH) agonist.

  • Iressa (gefitinib) is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.

  • Lynparza▼ (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.

  • TAGRISSO▼ (osimertinib) is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).

  • Zoladex® (goserelin) is a Luteinising Hormone-Releasing Hormone analogue (LHRHa). Zoladex® is available as a 3.6 mg implant and a 10.8 mg implant in a pre-filled syringe.

GB-12085 - May 2018